SEARCH

SEARCH BY CITATION

References

  • 1
    Koh HK, Charif M, Weinstock MA. Epidemiology and clinical manifestations of cutaneous T-cell lymphoma. Hematol. Oncol. Clin. North Am. 1995; 9; 943960.
  • 2
    Burg G, Kempf W. Cutaneous lymphomas, 1st edn. New York: Taylor & Francis, 2005.
  • 3
    Alibert JLM. Tableau du pian fongoide. Description des maladies de la peau, observées à l′Hôpital Saint-Louis et exposition des meilleurs méthodes suivies pour leur traitement. Paris: Barrois L′Ainé & Fils, 1806.
  • 4
    Bazin P. Leçons sur le traitement des maladies chroniques en général, affections de la peau en particulier, par l`emploi comparé des eaux minérales, de l``hydrothérapie et des moyens pharmaceutiques. Paris: Delahaye, 1870.
  • 5
    Sézary A, Bouvrain Y. Erythrodermie avecpresence de cellules monstueuses dansle dermeetlesang circulant. Bull. Soc. Fr. Dermatol. Syphiligr. 1938; 45; 254260.
  • 6
    Willemze R, Kerl H, Sterry W et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997; 90; 354371.
  • 7
    Willemze R, Jaffe ES, Burg G et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105; 37683785.
  • 8
    Burg G, Jaffe ES, Kempf W et al. WHO/EORTC classification of cutaneous lymphomas. In LeBoitP, BurgG, WeedonD et al. eds. World Health Organization classification of tumours. Pathology and genetics of skin tumors. Lyon: WHO IARC, 2006; 166.
  • 9
    Swerdlow SH, Campo E, Harris NL et al. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008.
  • 10
    Harris NL, Jaffe ES, Vardiman JW et al. Introduction. In SwerdlowSH, CampoE, HarrisNL et al. eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 1213.
  • 11
    Lennert K, Stein H, Kaiserling E. Cytological and functional criteria for the classification of malignant lymphomata. Br. J. Cancer 1975; 2; 2943.
  • 12
    Harris NL, Jaffe ES, Stein H et al. A revised European–American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84; 13611392.
  • 13
    Harris NL. Principles of the revised European–American Lymphoma Classification (from the International Lymphoma Study Group). Ann. Oncol. 1997; 8(Suppl. 2); 1116.
  • 14
    The non-Hodgkin’s lymphoma pathologic classification project. National Cancer Institute sponsored study of classification of non-Hodgkin’s lymphoma. Summary and description of Working Formulation for clinical usage. Cancer 1982; 49; 21122135.
  • 15
    Fink-Puches R, Zenahlik P, Back B et al. Primary cutaneous lymphomas: applicability of current classification schemes (European Organization for Research and Treatment of Cancer, World Health Organization) based on clinicopathologic features observed in a large group of patients. Blood 2002; 99; 800805.
  • 16
    Willemze R, Meijer CJ. EORTC classification for primary cutaneous lymphomas: the best guide to good clinical management. European Organization for Research and Treatment of Cancer. Am. J. Dermatopathol. 1999; 21; 265273.
  • 17
    Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36; 6986.
  • 18
    Jaffe ES, Harris NL, Stein H et al. Pathology and genetics of tumours of hematopoietic and lymphoid tissues. Lyon: IARC Press, 2001.
  • 19
    Sander CA, Flaig MJ, Jaffe ES. Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. Clin. Lymphoma 2001; 2; 86100.
  • 20
    Slater DN. The new World Health Organization classification of haematopoietic and lymphoid tumours: a dermatopathological perspective. Br. J. Dermatol. 2002; 147; 633639.
  • 21
    Slater DN. The new World Health Organization–European Organization for Research and Treatment of Cancer classification for cutaneous lymphomas: a practical marriage of two giants. Br. J. Dermatol. 2005; 153; 874880.
  • 22
    Burg G, Kempf W. Epidemiology. In BurgG, KempfW eds. Cutaneous lymphomas. New York: Taylor & Francis, 2005; 1320.
  • 23
    Massone C, Kodama K, Kerl H et al. Histopathologic features of early (patch) lesions of mycosis fungoides: a morphologic study on 745 biopsy specimens from 427 patients. Am. J. Surg. Pathol. 2005; 29; 550560.
  • 24
    Kazakov DV, Burg G, Kempf W. Clinicopathological spectrum of mycosis fungoides. J. Eur. Acad. Dermatol. Venereol.. 2004; 18; 397415.
  • 25
    Hodak E, David M, Maron L et al. CD4/CD8 double-negative epidermotropic cutaneous T-cell lymphoma: an immunohistochemical variant of mycosis fungoides. J. Am. Acad. Dermatol. 2006; 55; 276284.
  • 26
    Massone C, Crisman G, Kerl H et al. The prognosis of early mycosis fungoides is not influenced by phenotype and T-cell clonality. Br. J. Dermatol. 2008; 159; 881886.
  • 27
    Flaig MJ, Cerroni L, Schuhmann K et al. Follicular mycosis fungoides. A histopathologic analysis of nine cases. J. Cutan. Pathol. 2001; 28; 525530.
  • 28
    Van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch. Dermatol. 2002; 138; 191198.
  • 29
    Kempf W, Ostheeren-Michaelis S, Paulli M et al. Granulomatous mycosis fungoides and granulomatous slack skin: a multicenter study of the Cutaneous Lymphoma Histopathology Task Force Group of the European Organization for Research and Treatment of Cancer (EORTC). Arch. Dermatol. 2008; 144; 16091617.
  • 30
    Haghighi B, Smoller BR, LeBoit PE et al. Pagetoid reticulosis (Woringer–Kolopp disease): an immunophenotypic, molecular, and clinicopathologic study. Mod. Pathol. 2000; 13; 502510.
  • 31
    Trautinger F, Knobler R, Willemze R et al. EORTC consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome. Eur. J. Cancer 2006; 42; 10141030.
  • 32
    Russell-Jones R, Whittaker S. Sezary syndrome: diagnostic criteria and therapeutic options. Semin. Cutan. Med. Surg. 2000; 19; 100108.
  • 33
    Trotter MJ, Whittaker SJ, Orchard GE et al. Cutaneous histopathology of Sezary syndrome: a study of 41 cases with a proven circulating T-cell clone. J. Cutan. Pathol. 1997; 24; 286291.
  • 34
    Buechner SA, Winkelmann RK. Sezary syndrome. A clinicopathologic study of 39 cases. Arch. Dermatol. 1983; 119; 979986.
  • 35
    Shapiro PE, Pinto FJ. The histologic spectrum of mycosis fungoides/Sezary syndrome (cutaneous T-cell lymphoma). A review of 222 biopsies, including newly described patterns and the earliest pathologic changes. Am. J. Surg. Pathol. 1994; 18; 645667.
  • 36
    Vonderheid EC, Bernengo MG, Burg G et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J. Am. Acad. Dermatol. 2002; 46; 95106.
  • 37
    Kempf W, Willemze R, Jaffe ES et al. CD30+ T-cell lymphoproliferative disorders. In LeBoitP, BurgG, WeedonD et al. eds. World Health Organization classification of tumours. Pathology and genetics of skin tumours. Lyon: IARC Press, 2006; 179181.
  • 38
    Bekkenk MW, Geelen FA, Van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95; 36533661.
  • 39
    Kempf W, Levi E, Kamarashev J et al. Fascin expression in CD30-positive cutaneous lymphoproliferative disorders. J. Cutan. Pathol. 2002; 29; 295300.
  • 40
    El Shabrawi-Caelen L, Kerl H, Cerroni L. Lymphomatoid papulosis: reappraisal of clinicopathologic presentation and classification into subtypes A, B, and C. Arch. Dermatol. 2004; 140; 441447.
  • 41
    Assaf C, Hirsch B, Wagner F et al. Differential expression of TRAF1 aids in the distinction of cutaneous CD30-positive lymphoproliferations. J. Invest. Dermatol. 2007; 127; 18981904.
  • 42
    Kempf W, Kutzner H, Cozzio A et al. MUM1 expression in cutaneous CD30+ lymphoproliferative disorders: a valuable tool for the distinction between lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma. Br. J. Dermatol. 2008; 158; 12801287.
  • 43
    Benner MF, Jansen PM, Meijer CJ, Willemze R. Diagnostic and prognostic evaluation of phenotypic markers TRAF1, MUM1, BCL2 and CD15 in cutaneous CD30-positive lymphoproliferative disorders. Br. J. Dermatol. 2009; 161; 121127.
  • 44
    Massone C, El-Shabrawi-Caelen L, Kerl H et al. The morphologic spectrum of primary cutaneous anaplastic large T-cell lymphoma: a histopathologic study on 66 biopsy specimens from 47 patients with report of rare variants. J. Cutan. Pathol. 2008; 35; 4653.
  • 45
    DeCoteau JF, Butmarc JR, Kinney MC et al. The t(2;5) chromosomal translocation is not a common feature of primary cutaneous CD30+ lymphoproliferative disorders: comparison with anaplastic large-cell lymphoma of nodal origin. Blood 1996; 87; 34373441.
  • 46
    Herbst H, Sander C, Tronnier M et al. Absence of anaplastic lymphoma kinase (ALK) and Epstein–Barr virus gene products in primary cutaneous anaplastic large cell lymphoma and lymphomatoid papulosis. Br. J. Dermatol. 1997; 137; 680686.
  • 47
    Burg G, Kempf W, Kazakov DV et al. Pyogenic lymphoma of the skin: a peculiar variant of primary cutaneous neutrophil-rich CD30+ anaplastic large-cell lymphoma. Clinicopathological study of four cases and review of the literature. Br. J. Dermatol. 2003; 148; 580586.
  • 48
    Willemze R, Jansen PM, Cerroni L et al. Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood 2008; 111; 838845.
  • 49
    Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97; 610627.
  • 50
    Bekkenk MW, Vermeer MH, Jansen PM et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003; 102; 22132219.
  • 51
    Arnulf B, Copie-Bergman C, Delfau-Larue MH et al. Nonhepatosplenic gammadelta T-cell lymphoma: a subset of cytotoxic lymphomas with mucosal or skin localization. Blood 1998; 91; 17231731.
  • 52
    Berti E, Tomasini D, Vermeer MH et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am. J. Pathol. 1999; 155; 483492.
  • 53
    Beltraminelli H, Leinweber B, Kerl H et al. Primary cutaneous CD4+ small-/medium-sized pleomorphic T-cell lymphoma: a cutaneous nodular proliferation of pleomorphic T lymphocytes of undetermined significance? A study of 136 cases Am. J. Dermatopathol. 2009; 31; 317322.
  • 54
    Friedmann D, Wechsler J, Delfau MH et al. Primary cutaneous pleomorphic small T-cell lymphoma. A review of 11 cases. The French Study Group on Cutaneous Lymphomas. Arch. Dermatol. 1995; 131; 10091015.
  • 55
    Rodriguez Pinilla SM, Roncador G, Rodriguez-Peralto JL et al. Primary cutaneous CD4+ small/medium-sized pleomorphic T-cell lymphoma expresses follicular T-cell markers. Am. J. Surg. Pathol. 2009; 33; 8190.
  • 56
    Garcia-Herrera A, Colomo L, Camos M et al. Primary cutaneous small/medium CD4+ T-cell lymphomas: a heterogeneous group of tumors with different clinicopathologic features and outcome. J. Clin. Oncol. 2008; 26; 33643371.
  • 57
    Kempf W, Ralfkiaer E, Duncan LM et al. Cutaneous marginal zone B-cell lymphoma. In LeBoitP, BurgG, WeedonD et al. eds. World Health Organization classification of tumours. Pathology and genetics of skin tumors. Lyon: WHO IARC, 2006; 194195.
  • 58
    Isaacson PG, Chott A, Nakamura S et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma). In SwerdlowSH, CampoE, HarrisNL et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 214217.
  • 59
    Van Maldegem F, Van Dijk R, Wormhoudt TA et al. The majority of cutaneous marginal zone B-cell lymphomas expresses class-switched immunoglobulins and develop in a T-helper type 2 inflammatory environment. Blood 2008; 112; 33553361.
  • 60
    Takino H, Li C, Hu S et al. Primary cutaneous marginal zone B-cell lymphoma: a molecular and clinicopathological study of cases from Asia, Germany, and the United States. Mod. Pathol. 2008; 21; 15171526.
  • 61
    Leinweber B, Colli C, Chott A et al. Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern. Am. J. Dermatopathol. 2004; 26; 413.
  • 62
    Kutzner H, Kerl H, Pfaltz MC, Kempf W. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: diagnostic and pathogenetic implications. Am. J. Surg. Pathol. 2009; 33; 13071313.
  • 63
    Hoefnagel JJ, Vermeer MH, Jansen PM et al. Primary cutaneous marginal zone B-cell lymphoma: clinical and therapeutic features in 50 cases. Arch. Dermatol. 2005; 141; 11391145.
  • 64
    Golling P, Cozzio A, Dummer R et al. Primary cutaneous B-cell lymphomas—clinicopathological, prognostic and therapeutic characterisation of 54 cases according to the WHO-EORTC classification and the ISCL/EORTC TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome. Leuk. Lymphoma 2008; 49; 10941103.
  • 65
    Senff NJ, Noordijk EM, Kim YH et al. European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas. Blood 2008; 112; 16001609.
  • 66
    Cozzio A, Kempf W, Schmid-Meyer R et al. Intra-lesional low-dose interferon alpha2a therapy for primary cutaneous marginal zone B-cell lymphoma. Leuk. Lymphoma 2006; 47; 865869.
  • 67
    Cerroni L, Zöchling N, Putz B et al. Infection by Borrelia burgdorferi and cutaneous B-cell lymphoma. J. Cutan. Pathol. 1997; 24; 457461.
  • 68
    Michaelis S, Kazakov DV, Schmid M et al. Hepatitis C and G viruses in B-cell lymphomas of the skin. J. Cutan. Pathol. 2003; 30; 369372.
  • 69
    Kempf W, Kerl H, Kutzner H. CD123-positive plasmacytoid dendritic cells in primary cutaneous marginal zone B-cell lymphoma: a crucial role and a new lymphoma paradigm. Am. J. Dermatopathol. 2009 (in press).
  • 70
    Cerroni L, Arzberger E, Putz B et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood 2000; 95; 39223928.
  • 71
    Senff NJ, Hoefnagel JJ, Jansen PM et al. Reclassification of 300 primary cutaneous B-Cell lymphomas according to the new WHO-EORTC classification for cutaneous lymphomas: comparison with previous classifications and identification of prognostic markers. J. Clin. Oncol. 2007; 25; 15811587.
  • 72
    Grange F, Beylot-Barry M, Courville P et al. Primary cutaneous diffuse large B-cell lymphoma, leg type: clinicopathologic features and prognostic analysis in 60 cases. Arch. Dermatol. 2007; 143; 11441150.
  • 73
    Kodama K, Massone C, Chott A et al. Primary cutaneous large B-cell lymphomas: clinicopathologic features, classification, and prognostic factors in a large series of patients. Blood 2005; 106; 24912497.
  • 74
    Petrella T, Bagot M, Willemze R et al. Blastic NK-cell lymphomas (agranular CD4+ CD56+ hematodermic neoplasms): a review. Am. J. Clin. Pathol. 2005; 123; 662675.
  • 75
    Petrella T, Comeau MR, Maynadie M et al. ‘Agranular CD4+ CD56+ hematodermic neoplasm’ (blastic NK-cell lymphoma) originates from a population of CD56+ precursor cells related to plasmacytoid monocytes. Am. J. Surg. Pathol. 2002; 26; 852862.
  • 76
    Facchetti F, Jones DM, Petrella T. Blastic plasmacytoid dendritic cell neoplasm. In SwerdlowSH, CampoE, HarrisNL et al. eds. World Health Organization classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon: IARC Press, 2008; 145147.
  • 77
    Kazakov DV, Mentzel T, Burg G et al. Blastic natural killer-cell lymphoma of the skin associated with myelodysplastic syndrome or myelogenous leukaemia: a coincidence or more? Br. J. Dermatol. 2003; 149; 869876.
  • 78
    Kempf W. CD30+ lymphoproliferative disorders: histopathology, differential diagnosis, new variants, and simulators. J. Cutan. Pathol. 2006; 33(Suppl. 1); 5870.
  • 79
    UICC. TNM classification of malignant tumors, 6th edn. New York: Wiley-Liss, 2002.
  • 80
    Olsen E, Vonderheid E, Pimpinelli N et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110; 17131722.
  • 81
    Kim YH, Willemze R, Pimpinelli N et al. TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007; 110; 479484.
  • 82
    Senff NJ, Willemze R. The applicability and prognostic value of the new TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: results on a large cohort of primary cutaneous B-cell lymphomas and comparison with the system used by the Dutch Cutaneous Lymphoma Group. Br. J. Dermatol. 2007; 157; 12051211.
  • 83
    Benner MF, Willemze R. Bone marrow examination has limited value in the staging of patients with an anaplastic large cell lymphoma first presenting in the skin. Retrospective analysis of 107 patients. Br. J. Dermatol. 2008; 159; 11481151.
  • 84
    Senff NJ, Kluin-Nelemans HC, Willemze R. Results of bone marrow examination in 275 patients with histological features that suggest an indolent type of cutaneous B-cell lymphoma. Br. J. Haematol. 2008; 142; 5256.
  • 85
    Ferreri AJ, Campo E, Seymour JF et al. Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the ‘cutaneous variant’. Br. J. Haematol. 2004; 127; 173183.
  • 86
    Petrella T, Maubec E, Cornillet-Lefebvre P et al. Indolent CD8-positive lymphoid proliferation of the ear: a distinct primary cutaneous T-cell lymphoma? Am. J. Surg. Pathol. 2007; 31; 18871892.
  • 87
    Ventura RA, Martin-Subero JI, Jones M et al. FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue. J. Mol. Diagn. 2006; 8; 141151.
  • 88
    Hahtola S, Burghart E, Jeskanen L et al. Clinicopathological characterization and genomic aberrations in subcutaneous panniculitis-like T-cell lymphoma. J. Invest. Dermatol. 2008; 128; 23042309.
  • 89
    Droc C, Cualing HD, Kadin ME. Need for an improved molecular/genetic classification for CD30+ lymphomas involving the skin. Cancer Control 2007; 14; 124132.
  • 90
    Sandberg Y, Van Gastel-Mol EJ, Verhaaf B et al. BIOMED-2 multiplex immunoglobulin/T-cell receptor polymerase chain reaction protocols can reliably replace Southern blot analysis in routine clonality diagnostics. J. Mol. Diagn. 2005; 7; 495503.
  • 91
    Huang Y, Moreau A, Dupuis J et al. Peripheral T-cell lymphomas with a follicular growth pattern are derived from follicular helper T cells (TFH) and may show overlapping features with angioimmunoblastic T-cell lymphomas. Am. J. Surg. Pathol. 2009; 33; 682690.